Related Experiment Video
Updated: Aug 25, 2025
Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes
Published on: December 19, 2020
Multi-valent pneumococcal conjugate vaccine for global health: From problem to platform to production
Anup Datta1, Kapil Kapre1,2, Indah Andi-Lolo1,3
1Bacterial Vaccine R&D, Inventprise, Inc., Redmond, WA, USA.
Insights
Inventprise is developing a 25-valent pneumococcal conjugate vaccine to combat childhood pneumonia and meningitis. This innovative vaccine aims for broad serotype coverage and affordability, improving global health equity.
Area of Science:
- Vaccinology
- Pediatric Infectious Diseases
- Biotechnology
Background:
- Childhood bacterial meningitis and pneumonia are major causes of mortality in children globally.
- High vaccine development and production costs hinder accessibility and health equity.
- Existing vaccines may not cover all prevalent pathogenic pneumococcal serotypes.
Purpose of the Study:
- To introduce Inventprise's 25-valent pneumococcal conjugate vaccine candidate.
- To address the need for broader coverage and more affordable vaccines.
- To overcome barriers in vaccine availability and global disease prevention.
Main Methods:
- Development of a 25-valent pneumococcal conjugate vaccine candidate.
- Utilization of the patented Hz-PEG-Hz linker technology platform.
- Implementation of innovative automation and controlled manufacturing processes to reduce costs.
Main Results:
- The vaccine candidate is designed for broad coverage against pathogenic pneumococcal serotypes.
- The Hz-PEG-Hz linker technology is patented.
- Automation and controlled manufacturing aim to mitigate high capital and workforce costs.
Conclusions:
- Inventprise's vaccine candidate offers a potential solution for reducing the burden of pneumococcal disease.
- The technology aims to improve vaccine affordability and accessibility, particularly in resource-limited settings.
- Innovation in vaccine manufacturing is crucial for enhancing global health equity.
Abstract:
Childhood bacterial meningitis and pneumonia represent leading causes of mortality, with the latter persisting as one of the top causes of mortality for children under 5 y of age. The prohibitive costs of developing and producing broader spectrum conjugate vaccines impact availability and affordability, resulting in a barrier to health equity and access to disease preventing vaccines, which restrict global health disease prevention efforts. Inventprise was founded in response to the need for innovation that can help reduce disease burden with improved coverage and more affordable vaccines. Inventprise 25-valent pneumococcal conjugate vaccine candidate with the patented Hz-PEG-Hz linker technology platform is expected to provide the broadest coverage against pathogenic pneumococcal serotypes encountered by populations regardless of where they live. The innovative automation technology and tightly controlled manufacturing requirements were implemented to mitigate the high capital cost for constructing a manufacturing facility in the United States, in addition to the prohibitive cost for the workforce required for running a complex plant.
Related Concept Videos
02:50Conjugated Proteins
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:30Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:51Vaccinations